Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

BACKGROUND: ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. Our retrospective study aimed to compare the efficacy of chemotherapy and cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongchang, Zhang, Xiangyu, Zhang, Ruiguang, Xu, Qinqin, Yang, Haiyan, Lizaso, Analyn, Xu, Chunwei, Liu, Jun, Wang, Wenxian, Ou, Sai-Hong Ignatius, Zhang, Jiexia, Song, Zhengbo, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436549/
https://www.ncbi.nlm.nih.gov/pubmed/34511132
http://dx.doi.org/10.1186/s12916-021-02082-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436549/
https://www.ncbi.nlm.nih.gov/pubmed/34511132
http://dx.doi.org/10.1186/s12916-021-02082-6

Ejemplares similares